New phosphosite-specific antibodies to unravel the role of GRK phosphorylation in dopamine D2 receptor regulation and signaling
The dopamine D 2 receptor (D 2 R) is the target of drugs used to treat the symptoms of Parkinson’s disease and schizophrenia. The D 2 R is regulated through its interaction with and phosphorylation by G protein receptor kinases (GRKs) and interaction with arrestins. More recently, D 2 R arrestin-med...
Gespeichert in:
Veröffentlicht in: | Scientific reports 2021-04, Vol.11 (1), p.1-17, Article 8288 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The dopamine D
2
receptor (D
2
R) is the target of drugs used to treat the symptoms of Parkinson’s disease and schizophrenia. The D
2
R is regulated through its interaction with and phosphorylation by G protein receptor kinases (GRKs) and interaction with arrestins. More recently, D
2
R arrestin-mediated signaling has been shown to have distinct physiological functions to those of G protein signalling. Relatively little is known regarding the patterns of D
2
R phosphorylation that might control these processes. We aimed to generate antibodies specific for intracellular D
2
R phosphorylation sites to facilitate the investigation of these mechanisms. We synthesised double phosphorylated peptides corresponding to regions within intracellular loop 3 of the hD
2
R and used them to raise phosphosite-specific antibodies to capture a broad screen of GRK-mediated phosphorylation. We identify an antibody specific to a GRK2/3 phosphorylation site in intracellular loop 3 of the D
2
R. We compared measurements of D
2
R phosphorylation with other measurements of D
2
R signalling to profile selected D
2
R agonists including previously described biased agonists. These studies demonstrate the utility of novel phosphosite-specific antibodies to investigate D
2
R regulation and signalling. |
---|---|
ISSN: | 2045-2322 2045-2322 |
DOI: | 10.1038/s41598-021-87417-2 |